MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)。

RO4929097

CAS No. : 847925-91-1

MCE 國際站：RO4929097

產(chǎn)品活性：RO4929097 (RG-4733) 是一種 γ secretase 抑制劑，IC₅₀ 值為 4 nM，能夠抑制細胞內(nèi) Aβ40 的產(chǎn)生和 Notch 活性，EC₅₀ 值分別為 14 nM 和 5 nM。

研究領(lǐng)域：Neuronal Signaling  |  Stem Cell/Wnt

作用靶點：γ-secretase  |  Notch

In Vitro: RO4929097 inhibits the production of ICN reducing the expression of the downstream Notch target, Hes1, producing a less transformed morphology in A549 cells. RO4929097 inhibits Notch processing in human tumor-derived cells.?RO4929097 (1 µM) inhibits the growth of breast cancer cells, and the inhibition is 20% for SUM149 and 10% for SUM190 cells. RO4929097 does not have a marked effect in invasiveness of SUM149 cells. RO4929097 significantly reduces colony formation by both cell lines with the effect being more notable in SUM149 than by SUM190 cells. RO4929097 inhibits proliferation, anchorage independent growth, and sphere formation of primary melanoma cells in vitro.

In Vivo: RO4929097 (3-60 mg/kg, p.o.) results in significant tumor growth inhibition in nude mice bearing A549 NSCLC xenografts, compared with vehicle-treated animals. When mice are treated with 60 mg/kg RO4929097 twice daily with the 7+/14- schedule, treatment initially causes regression of established A549 tumors. RO4929097 impairs the growth of primary melanoma cells in vivo. The percentage of secondary tumors formed by RO4929097-treated cells is lower; the secondary tumors formed by RO4929097-treated cells are smaller; a significant delay in tumor formation by the RO4929097-treated cells compared to the vehicle-treated ones is observed in mice injected with 10⁴ cells in vivo.

相關(guān)產(chǎn)品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Neuronal Signaling Compound Library  |  Stem Cell Signaling Compound Library  |  Wnt/Hedgehog/Notch Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Antiviral Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Differentiation Inducing Compound Library  |  Reprogramming Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Neurodegenerative Disease-related Compound Library  |  Angiogenesis-Related Compound Library  |  Transcription Factor-Targeted Library  |  Anti-Liver Cancer Compound Library   |  Anti-Colorectal Cancer Compound Library   |  Anti-Prostate Cancer Compound Library  |  Cancer Stem Cells Compound Library  |  Membrane Protein-targeted Compound Library  |  DAPT  |  Valproic acid  |  LY-411575  |  Compound E  |  Jagged-1 (188-204) (TFA)  |  YO-01027  |  Nirogacestat  |  Limantrafin  |  Tangeretin  |  Carvacrol  |  Crenigacestat  |  RBPJ Inhibitor-1  |  IMR-1  |  Semagacestat  |  MK-0752  |  Prednisone acetate  |  L-685458  |  Psoralidin  |  BMS-906024  |  Tarlatamab  |  E 2012  |  Sulindac sulfide  |  Bruceine D  |  FLI-06  |  Avagacestat  |  Rovalpituzumab  |  BPN-15606  |  MRK-560  |  ZLDI-8

熱門產(chǎn)品線：重組蛋白  |  化合物庫  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標記物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds